Nouscom receives approval to begin Phase 1b trials of NOUS-PEV, a novel personalized cancer immunotherapy
BASEL, Switzerland – 11th March 2021: Nouscom, a clinical stage immuno-oncology biotech developing next generation viral-vector based immunotherapies, today announces it has received approval [...]